Your browser doesn't support javascript.
loading
An open-label, pilot study of veliparib and lapatinib in patients with metastatic, triple-negative breast cancer.
Stringer-Reasor, Erica M; May, Jori E; Olariu, Eva; Caterinicchia, Valerie; Li, Yufeng; Chen, Dongquan; Della Manna, Deborah L; Rocque, Gabrielle B; Vaklavas, Christos; Falkson, Carla I; Nabell, Lisle M; Acosta, Edward P; Forero-Torres, Andres; Yang, Eddy S.
Afiliação
  • Stringer-Reasor EM; Department of Medicine, Division of Hematology Oncology, University of Alabama at Birmingham, Birmingham, AL, USA.
  • May JE; Department of Medicine, Division of Hematology Oncology, University of Alabama at Birmingham, Birmingham, AL, USA.
  • Olariu E; Department of Medicine, Brookwood Baptist Health, Birmingham, AL, USA.
  • Caterinicchia V; Department of Medicine, Division of Hematology Oncology, University of Alabama at Birmingham, Birmingham, AL, USA.
  • Li Y; Department of Medicine, Division of Hematology Oncology, University of Alabama at Birmingham, Birmingham, AL, USA.
  • Chen D; Department of Medicine, Division of Hematology Oncology, University of Alabama at Birmingham, Birmingham, AL, USA.
  • Della Manna DL; Department of Radiation Oncology, University of Alabama at Birmingham, Birmingham, AL, USA.
  • Rocque GB; Department of Medicine, Division of Hematology Oncology, University of Alabama at Birmingham, Birmingham, AL, USA.
  • Vaklavas C; Department of Medicine, Division of Hematology Oncology, University of Alabama at Birmingham, Birmingham, AL, USA.
  • Falkson CI; Department of Medicine, Division of Hematology Oncology, University of Alabama at Birmingham, Birmingham, AL, USA.
  • Nabell LM; Department of Medicine, Division of Hematology Oncology, University of Alabama at Birmingham, Birmingham, AL, USA.
  • Acosta EP; Department of Pharmacology/Toxicology, University of Alabama at Birmingham, Birmingham, AL, USA.
  • Forero-Torres A; Department of Medicine, Division of Hematology Oncology, University of Alabama at Birmingham, Birmingham, AL, USA.
  • Yang ES; Department of Radiation Oncology, University of Alabama at Birmingham, Birmingham, AL, USA. shyang@uabmc.edu.
Breast Cancer Res ; 23(1): 30, 2021 03 04.
Article em En | MEDLINE | ID: mdl-33663560
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Neoplasias de Mama Triplo Negativas Tipo de estudo: Prognostic_studies Limite: Adult / Female / Humans / Middle aged Idioma: En Revista: Breast Cancer Res Assunto da revista: NEOPLASIAS Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Estados Unidos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Neoplasias de Mama Triplo Negativas Tipo de estudo: Prognostic_studies Limite: Adult / Female / Humans / Middle aged Idioma: En Revista: Breast Cancer Res Assunto da revista: NEOPLASIAS Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Estados Unidos